Market Overview

Goldman Sachs Gets Firm On Solid Biosciences

Goldman Sachs Gets Firm On Solid Biosciences
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
55 Biggest Movers From Yesterday
3 Things In Biotech, March 16: Lilly's Advisory, Solid's Downfall, Inovio's Heps Up (Seeking Alpha)

Just weeks into its life as a publicly traded company, Solid Biosciences Inc (NASDAQ: SLDB) caught the eyes of four analysts who assumed coverage Tuesday with a mix of Holds and Buys.

Here is what one of the more bearish critics had to say.

The Rating

Goldman Sachs analyst Salveen Richter initiated coverage on Solid Biosciences with a Neutral rating and a $31 price target.

The Thesis

The biotech company’s Duchenne muscular dystrophy portfolio is led by SGT-001, a gene therapy competing with Sarepta Therapeutics Inc (NASDAQ: SRPT) and Pfizer Inc. (NYSE: PFE)-Bamboo treatments.

Solid Biosciences will release Phase 1/2 interim data for its candidate in the first half of 2019 to be clinically compared with Sarepta’s interim Phase 1/2 results delivering proof of concept in the back half of 2018.

“We acknowledge SGT-001 could be a game-changing therapy for DMD patients and estimate $3.1 billion in global risk-unadjusted peak sales,” Richter wrote in a Tuesday note.

By his assessment, risks include a lack of near-term drivers coupled with ambiguity around resolution of the FDA’s partial clinical hold on high-dose manufacturing; safe, systemic administration at a high dose; and ownership of intellectual property for the AAV9 delivery method.

Price Action

At time of publication, shares of Solid Biosciences were trading down 3 percent at $24.19.

Related Links:

19 Biotech Stocks With Clinical Trial Outcomes In February

Attention Biotech Investors: February PDUFA Catalysts Come Calling

Latest Ratings for SLDB

Mar 2018JP MorganDowngradesNeutralUnderweight
Feb 2018Chardan CapitalInitiates Coverage OnBuy
Feb 2018Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for SLDB
View the Latest Analyst Ratings

Posted-In: DMD Duchenne Muscular Dystrophy Goldman Sachs Salveen RichterAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga


Related Articles (PFE + SLDB)

View Comments and Join the Discussion!